The 21st Century Cures bill is a bipartisan initiative that is aimed to streamline and hasten the drug and device approval process and promote medical innovation.
Initiated by a collaborative effort between Fred Upton (R-Mich) and Diana DeGette (D-Colo), provisions of the 21st Century Cures Initiative would provide support to the FDA and the National Institutes of Health, so medical innovations made be scientists find the light of day.
On Thursday, The House Energy and Commerce Committee, chaired by Upton, unanimously approved the bill shortly after reaching a bipartisan $13 billion deal to pay for the legislation.
Several professional organizations are now providing their response to the bills provisions.
Read the complete article on The Hill: http://bit.ly/1AjOR2u
AD Progression Adversely Influenced by Outdoor Air Pollution
February 2nd 2023With atopic dermatitis (AD) prevalence increasing around the world, primarily in developing countries, investigators evaluated the potential for pollution to have an impact on development of the chronic skin condition among an adult population.
Read More
Promoting Health Equity and Resiliency in Trauma-Affected Communities
January 31st 2023On this episode of Managed Care Cast, we speak with Reverend Paul Abernathy, CEO of the Neighborhood Resilience Project and board member of UPMC for You, who discusses his experiences in promoting health and resiliency in trauma-affected communities, as well as challenges related to access and accessibility of care and medical mistrust.
Listen
Merck & Co. and Eli Lilly & Co. report sales loss for COVID-19 treatments; Republican state attorneys general tell CVS and Walgreens that mailing mifepristone might break the law; exposure to air pollution over time is associated with a rise in incidence of depression and anxiety.
Read More
Examining Telehealth Uptake to Increase Equitable Care Access
January 26th 2023To mark the publication of The American Journal of Managed Care®’s 12th annual health IT issue, on this episode of Managed Care Cast, we speak with Christopher M. Whaley, PhD, health care economist at the RAND Corporation, who focuses on health economics issues, including the influence of the COVID-19 pandemic on health care delivery.
Listen
Periostin Bests Eosinophil Count for Biomarker Predictability in ECRS
February 2nd 2023Known to be a contributing factor to polyp development at high levels, periostin’s potential as a biomarker for eosinophilic chronic rhinosinusitis (ECRS) severity was investigated in a new study in which outcomes were compared between patients who had ECRS and those with non-ECRS.
Read More
2 Clarke Drive
Cranbury, NJ 08512